Washington Trust’s Novavax NVAX Stock Holding History

Washington Trust’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-618	Closed	-$23K	–	230
2018 Q3	$23K	Hold	618	–	–	﹤0.01%	229
2018 Q2	$17K	Sell	618 -617	-50%	-$20.9K	﹤0.01%	602
2018 Q1	$52K	Hold	1,235	–	–	﹤0.01%	216
2017 Q4	$31K	Hold	1,235	–	–	﹤0.01%	223
2017 Q3	$28K	Hold	1,235	–	–	﹤0.01%	215
2017 Q2	$28K	Hold	1,235	–	–	﹤0.01%	208
2017 Q1	$32K	Hold	1,235	–	–	﹤0.01%	203
2016 Q4	$31K	Hold	1,235	–	–	﹤0.01%	211
2016 Q3	$51K	Buy	+1,235	New	+$159K	﹤0.01%	205

Other funds holding NVAX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Washington Trust's NVAX Position: Q4 2018 in Review

Washington Trust sold out of Novavax (NVAX) in Q4 2018, closing a stake of 618 shares — an estimated $23K sold.

Washington Trust first reported a position in NVAX in Q3 2016 and held it in 9 quarters. The position peaked at $52K in Q1 2018. 167 funds tracked by Wall St. Rank hold NVAX as of Q4 2018.

Washington Trust reported no remaining Novavax position as of Q4 2018 after selling out during the quarter.
Washington Trust sold 618 Novavax shares in Q4 2018, an estimated $23K.
Washington Trust first reported a position in Novavax in Q3 2016 and held it in 9 quarters.
Washington Trust's Novavax position peaked at $52K in Q1 2018.
167 funds tracked by Wall St. Rank held Novavax as of Q4 2018.

Based on Washington Trust's 13F filing for Q4 2018, filed 11 Feb 2019.